SITC’s Guide to Managing Immunotherapy Toxicity

Więcej o książce

The Society for Immunotherapy of Cancer's handbook, SITC’s Guide to Managing Immunotherapy Toxicity, serves as a practical reference for managing side effects linked to FDA-approved cancer immunotherapy drugs. It is divided into two parts: Part I offers chapter-based overviews of immune checkpoint inhibitors, including anti-CTLA4 and anti-PD1/PD-L1 agents, along with approved combinations. These chapters detail mechanisms of action, indications, and toxicities encountered in early, advanced, and metastatic cancer patients. Part II focuses on common and uncommon toxicities affecting major organ sites. It begins with a general summary of management principles, followed by specific chapters on toxicities such as rash, mucosal irritation, joint and muscle toxicity, diarrhea, pneumonitis, endocrine, neurological, cardiac, renal, hematologic, and ocular toxicities. Each chapter provides guidance on assessing and treating these toxicities, with detailed summary tables for quick reference. Additionally, Part II addresses the management of special patient populations, including those with autoimmune diseases and geriatric patients, as well as treatment for fatigue and the financial impact of care. Written by leading experts in immuno-oncology, this text is an essential resource for clinical oncologists, emergency physicians, and other medical practitioners in both hospital and community settings, especially as immune checkpoint inh